Sorafenib-Based Drug Delivery Systems: Applications and Perspectives.
Lingyun WangMeihuan ChenXueguang RanHao TangDerong CaoPublished in: Polymers (2023)
As a Food and Drug Administration (FDA)-approved molecular-targeted chemotherapeutic drug, sorafenib (SF) can inhibit angiogenesis and tumor cell proliferation, leading to improved patient overall survival of hepatocellular carcinoma (HCC). In addition, SF is an oral multikinase inhibitor as a single-agent therapy in renal cell carcinoma. However, the poor aqueous solubility, low bioavailability, unfavorable pharmacokinetic properties and undesirable side effects (anorexia, gastrointestinal bleeding, and severe skin toxicity, etc.) seriously limit its clinical application. To overcome these drawbacks, the entrapment of SF into nanocarriers by nanoformulations is an effective strategy, which delivers SF in a target tumor with decreased adverse effects and improved treatment efficacy. In this review, significant advances and design strategies of SF nanodelivery systems from 2012 to 2023 are summarized. The review is organized by type of carriers including natural biomacromolecule (lipid, chitosan, cyclodextrin, etc.); synthetic polymer (poly(lactic- co -glycolic acid), polyethyleneimine, brush copolymer, etc.); mesoporous silica; gold nanoparticles; and others. Co-delivery of SF and other active agents (glypican-3, hyaluronic acid, apolipoprotein peptide, folate, and superparamagnetic iron oxide nanoparticles) for targeted SF nanosystems and synergistic drug combinations are also highlighted. All these studies showed promising results for targeted treatment of HCC and other cancers by SF-based nanomedicines. The outlook, challenges and future opportunities for the development of SF-based drug delivery are presented.
Keyphrases
- drug delivery
- cancer therapy
- hyaluronic acid
- gold nanoparticles
- cell proliferation
- iron oxide nanoparticles
- renal cell carcinoma
- drug administration
- mass spectrometry
- emergency department
- drug release
- risk assessment
- stem cells
- case report
- drug induced
- fatty acid
- cell therapy
- climate change
- single molecule
- cell cycle
- signaling pathway
- vascular endothelial growth factor
- human health
- current status